TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28249801

Group type: EXPERIMENTAL
Intervention: Impact loading + resistance training (ILRT)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Aerobic + resistance training (ART)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care/delayed exercise (DEL)
Number of subjects: 163
Study: 25433511

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23569175

Group type: EXPERIMENTAL
Intervention: Insulin glargine (GLA)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metabolite 1 (M1)
Number of subjects: 104

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 104
Study: 21185145

Group type: EXPERIMENTAL
Intervention: Medium heated humidifier (HH) setting
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Maximum heated humidifier (HH) setting
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bench study with no HH, HH at medium setting, and HH at maximum setting
Number of subjects: 23
Study: 19473225

Group type: EXPERIMENTAL
Intervention: Glutamate supplementation (500 mg three times daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 17899046

Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (0.25 mg, 0.5 mg, 1.2 mg, 2.5 mg, 5.0 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (0.5 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (1.2 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BAY 63‐9044 (highest two doses)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: BAY 63‐9044
Number of subjects: 45
Study: 15602801

Group type: EXPERIMENTAL
Intervention: Enhanced evening light (approximately 265 lux)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo dim light (approximately 2 lux)
Number of subjects: 47
Study: 10566581

Group type: EXPERIMENTAL
Intervention: Weinstein Enhanced Sensory Test (WEST)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament (SWM) test
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Disk-Criminator test
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Strauch's ten test
Number of subjects: 153
Study: 8877724

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide 300 mg/m2 on day -3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral cyclophosphamide 50 mg daily from days -14 to -3
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cyclophosphamide
Number of subjects: 0
Study: 1987817

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 144
Study: 6313025

Group type: EXPERIMENTAL
Intervention: Atropine 20 microgram kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glycopyrrolate 10 microgram kg‐1
Number of subjects: 20
Study: 3972647

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Dusodril)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Basic therapy (Dextran, Diazepam, and Vitamins)
Number of subjects: 100
Study: 30572526

Group type: EXPERIMENTAL
Intervention: Training group (received a 3-hour training session)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 27356642

Group type: EXPERIMENTAL
Intervention: Automated intermittent boluses of 10 ml of 0.2% ropivacaine every 60 mins for 48 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous infusion of 10 ml/h of 0.2% ropivacaine for 48 hours
Number of subjects: 60
Study: 24751920

Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy
Number of subjects: 2993
Study: 22850709

Group type: EXPERIMENTAL
Intervention: Latex membrane implant
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Sylastic® membrane implant
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group with no transitory implant
Number of subjects: 107
Study: 20406960

Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (highest tertile)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (moderate intensity)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (greater than median)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Lifetime physical activity (obese and overweight women)
Number of subjects: 915
Study: 18275580

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 200
Study: 15694220

Group type: EXPERIMENTAL
Intervention: Intensive communication with general practitioners (GPs) where consultants directly reported findings.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard practice where only inpatient referring physicians were informed of consultation findings.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intensive communication with GPs.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard practice communication.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Patients beginning psychotherapy.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Acceptance of psychotherapy.
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Requests for communication options by GPs.
Number of subjects: 67
Study: 12913186

Group type: EXPERIMENTAL
Intervention: KW-6002 (80 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: KW-6002
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10697970

Group type: EXPERIMENTAL
Intervention: Gait plate inlays
Number of subjects: 18
Study: 8788354

Group type: EXPERIMENTAL
Intervention: Self-Management Course-Ankylosing Spondylitis (SMC-AS)
Number of subjects: 0
Study: 1614072

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined therapy (enalapril 5 mg + felodipine 5 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Felodipine 5 mg added to enalapril 5 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Enalapril 5 mg added to felodipine 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 36
Study: 6599697

Group type: EXPERIMENTAL
Intervention: Nifedipine, 3 X 10‐20 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine + chlorthalidone, 25 to 50 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31250880

Group type: EXPERIMENTAL
Intervention: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 162
Study: 30256805

Group type: EXPERIMENTAL
Intervention: Self-reporting of occupational exposure to blood/body fluids
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Exposure to blood/body fluids
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Non-usage of safety protocols
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Psychological support after injuries
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Employer attention to needle-stick injuries
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Personal and management factors
Number of subjects: 548
Study: 27277115

Group type: EXPERIMENTAL
Intervention: Chlorophyll c2 (0.7 mg daily for 12 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 23684697

Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation
Number of subjects: 747

Group type: COMPARATOR
Intervention: No oxytocin augmentation
Number of subjects: 747
Study: 22858235

Group type: EXPERIMENTAL
Intervention: Paroxetine 20mg
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 20420787

Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Fesoterodine 28 mg
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 261
Study: 18611271

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) administered twice at eight-week intervals during the transmission season.
Number of subjects: 262

Group type: COMPARATOR
Intervention: No IPT (control group).
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the first 16 weeks of follow-up.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) during the subsequent transmission season.
Number of subjects: 262

Group type: COMPARATOR
Intervention: No IPT (control group) during the subsequent transmission season.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: In vivo response to treatment with SP.
Number of subjects: 262
Study: 16292205

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial fundoplication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total fundoplication
Number of subjects: 0
Study: 12124559

Group type: EXPERIMENTAL
Intervention: Standard treatment with additional antioxidants (Allopurinol, vitamin E and C, N‐acetylcysteine, and mannitol)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 22
Study: 10331884

Group type: EXPERIMENTAL
Intervention: Mild hypoxia (FIO2 = 0.187; approximately 1,000 m)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Change in SaO2 from normoxia to mild hypoxia
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Correlation of SaO2 during maximal exercise in normoxia
Number of subjects: 19
Study: 8696545

Group type: EXPERIMENTAL
Intervention: Groshong catheter (9.5F)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hickman catheter (7F)
Number of subjects: 20
Study: 1769413

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg, twice daily for 10 days
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Cephalexin 500 mg, twice daily for 10 days
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Cefadroxil 500 mg, twice daily for 10 days
Number of subjects: 330
Study: 7047707

Group type: EXPERIMENTAL
Intervention: Metaproterenol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 34
Study: 30792052

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 210
Study: 28525302

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily (lower-dose group)
Number of subjects: 1689

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily (higher-dose group)
Number of subjects: 1689

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1689
Study: 25575502

Group type: EXPERIMENTAL
Intervention: Randomized diet and antismoking trial
Number of subjects: 16203

Group type: EXPERIMENTAL
Intervention: Randomized drug treatment in mild-to-moderate hypertension
Number of subjects: 16203

Group type: EXPERIMENTAL
Intervention: Non-smoking behavior and low total cholesterol
Number of subjects: 16203
Study: 22882878

Group type: EXPERIMENTAL
Intervention: Two-sided ads for participants high in assessment orientation
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-sided ads for participants high in locomotion orientation
Number of subjects: 0
Study: 21248161

Group type: EXPERIMENTAL
Intervention: Intervention ICUs
Number of subjects: 9269

Group type: COMPARATOR
Intervention: Control ICUs
Number of subjects: 9269
Study: 19321506

Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine plus intravenous morphine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine plus oral morphine
Number of subjects: 22
Study: 17125605

Group type: EXPERIMENTAL
Intervention: Telbivudine 200 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Telbivudine 400 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg (single dose)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg (multiple doses for 8 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Telbivudine 800 mg
Number of subjects: 42
Study: 15552608

Group type: EXPERIMENTAL
Intervention: Prednicarbate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical steroids
Number of subjects: 0
Study: 11738277

Group type: EXPERIMENTAL
Intervention: Daily 400-microg folic acid supplement plus natural diet
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Increased dietary folate intake to 400 microg/day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo plus natural diet
Number of subjects: 126
Study: 9286744

Group type: COMPARATOR
Intervention: Candy bar (C1: 280 kcal, 36 g CHO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Fat-free fig bars (C2: 200 kcal, 44 g CHO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nonnutritive sweetened drink (C3: placebo)
Number of subjects: 13
Study: 8343260

Group type: EXPERIMENTAL
Intervention: BCG RIV (108 patients)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: BCG Pasteur (109 patients)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Follow-up only (110 patients)
Number of subjects: 327
Study: 3520795

Group type: EXPERIMENTAL
Intervention: 10-15 mg prednisone daily
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 29424484

Group type: COMPARATOR
Intervention: Cardiogenic shock group (n=9)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-shock group (n=52)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Controls (n=44)
Number of subjects: 61
Study: 27062938

Group type: EXPERIMENTAL
Intervention: Complete ST resolution before primary PCI
Number of subjects: 933

Group type: COMPARATOR
Intervention: Continuous ST elevations before primary PCI
Number of subjects: 933
Study: 26517404

Group type: EXPERIMENTAL
Intervention: Electronic reading (tablet and computer display at 100% and 330% zoom levels)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hard-copy reading (text in book position in silence and aloud, text pasted on the computer display)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electronic reading
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hard-copy reading
Number of subjects: 50
Study: 23745322

Group type: EXPERIMENTAL
Intervention: sL-selectin in patients with AMI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: sE-selectin in patients with AMI
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: sP-selectin in patients with AMI
Number of subjects: 27

Group type: COMPARATOR
Intervention: sE-selectin
Number of subjects: 27

Group type: COMPARATOR
Intervention: sP-selectin
Number of subjects: 27

Group type: COMPARATOR
Intervention: sL-selectin
Number of subjects: 27
Study: 20656516

Group type: EXPERIMENTAL
Intervention: Cerebrolysin 20 mL administered once daily for 24 weeks
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 242
Study: 19473603

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 p.m.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol extended-release capsules taken in the fasted state between 7:30 and 8:00 a.m. or p.m.
Number of subjects: 18
Study: 17303249

Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation (rTMS) at 90% of individual motor threshold, 5 sessions of 20 Hz rTMS with 800 stimuli/day for 1 week.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham treatment (control group).
Number of subjects: 19
Study: 15259895

Group type: COMPARATOR
Intervention: Lamivudine alone (150 mg/day for 96 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lamivudine plus interferon (10 MU three times a week for 24 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lamivudine alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lamivudine plus interferon
Number of subjects: 80
Study: 11703220

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9390697

Group type: EXPERIMENTAL
Intervention: Healthy preterm neonates
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy term neonates
Number of subjects: 100
Study: 8550858

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/co-polymer toothpaste
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorhexidine rinse
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline rinse
Number of subjects: 18
Study: 2693849

Group type: EXPERIMENTAL
Intervention: Magnesium chloride (62 mmol intravenously during the initial 48 h)
Number of subjects: 130
Study: 852337

Group type: EXPERIMENTAL
Intervention: Group 1: Isoniazid (5 to 6 mg/kg), Ethambutol (25 mg/kg), Rifampin (10 mg/kg) daily for 6 months
Number of subjects: 163

Group type: COMPARATOR
Intervention: Group 2: Same therapy as group 1 for 6 months, then Isoniazid (5 mg/kg three days per week) for an additional 6 months
Number of subjects: 163
Study: 30476321

Group type: EXPERIMENTAL
Intervention: Loop-mediated isothermal amplification (LAMP) assays for detection of APEC-associated virulence genes (sitA, traT, ompT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: LAMP assays
Number of subjects: 6
Study: 28189188

Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 24
Study: 25924592

Group type: EXPERIMENTAL
Intervention: Store-based intervention including employee trainings and infrastructure changes
Number of subjects: 369

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 369
Study: 26386787

Group type: EXPERIMENTAL
Intervention: ABSORB BVS
Number of subjects: 2262

Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting stents (EES)
Number of subjects: 2262
Study: 23880598

Group type: EXPERIMENTAL
Intervention: Docetaxel plus irinotecan
Number of subjects: 77
Study: 19682100

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 136
Study: 18519426

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9977

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 9977
Study: 16619360

Group type: EXPERIMENTAL
Intervention: STA-1 (80 g/kg/day, administered twice daily for 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (80 g/kg/day, administered twice daily for 6 months)
Number of subjects: 120
Study: 12791625

Group type: EXPERIMENTAL
Intervention: Active group (234 mg cocoa flavanols and procyanidins/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group (<= 6 mg cocoa flavanols and procyanidins/d)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 32
Study: 10983616

Group type: EXPERIMENTAL
Intervention: 50 microg b.i.d. HFA-BDP
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: 100 microg b.i.d. HFA-BDP
Number of subjects: 270

Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 270
Study: 9153458

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 100, 200, or 400 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) titrated up to 400 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7957540

Group type: EXPERIMENTAL
Intervention: 60 mg dexfenfluramine taken with 250 ml water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg fluoxetine pretreatment at -8 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg fluoxetine daily for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine alone 14 days after cessation of 14 days of fluoxetine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 0
Study: 3588052

Group type: EXPERIMENTAL
Intervention: Cisapride (0.3 mg/kg initial dose, followed by 0.15 mg/kg every 4 hr for 12 hr)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29089215

Group type: EXPERIMENTAL
Intervention: SCIPA 'Full-On' physical activity program
Number of subjects: 8
Study: 25344395

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with partial blood flow restriction (30% one-repetition-maximum)
Number of subjects: 13
Study: 24297981

Group type: EXPERIMENTAL
Intervention: Multifaceted podiatric medical intervention (home-based foot and ankle exercises, assistance with safe footwear, provision of prefabricated foot orthoses)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Multifaceted podiatric medical intervention
Number of subjects: 153
Study: 20587703

Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 238

Group type: COMPARATOR
Intervention: IL-7 tertile increase
Number of subjects: 238

Group type: COMPARATOR
Intervention: IL-2 tertile increase
Number of subjects: 238
Study: 18940401

Group type: EXPERIMENTAL
Intervention: Supervised exercise (6-month program with weekly training sessions)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Unsupervised exercise (6-month program)
Number of subjects: 17
Study: 16882538

Group type: EXPERIMENTAL
Intervention: UMTS base station-like exposure at 10 V/m
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control exposure (0 or 1 V/m)
Number of subjects: 117
Study: 12912818

Group type: EXPERIMENTAL
Intervention: Methionine-loading test (100 mg/kg body weight, administered orally)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 23